Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s179, 2023. DOI: 10.25251/skin.7.supp.179. Disponível em: https://skin.dermsquared.com/skin/article/view/1997. Acesso em: 19 apr. 2025.